Vi­da Ven­tures co-leads Dyne's $115M megaround for next-gen oli­go ther­a­pies aimed square­ly at mus­cles

Dyne Ther­a­peu­tics start­ed out last April with a mod­est $50 mil­lion to mine tar­get­ed mus­cle dis­ease ther­a­pies from its in-house con­ju­gate tech­nol­o­gy. The biotech has now con­vinced more in­vestors that it’s got gems on its hands, clos­ing $115 mil­lion in fresh fi­nanc­ing to push its next-gen oligonu­cleotide drugs in­to the clin­ic.

Joshua Brumm

Vi­da Ven­tures and Sur­vey­or Cap­i­tal led the round, joined by a group of oth­er new back­ers in­clud­ing Welling­ton Man­age­ment Com­pa­ny, Lo­gos Cap­i­tal and Franklin Tem­ple­ton.

At­las — where Dyne was in­cu­bat­ed — al­so re­turned along­side For­bion and MPM.

Ste­fan Vi­torovic, who co-found­ed Vi­da with Arie Bellde­grun and oth­ers, took the lead on this one. Dyne’s FORCE plat­form match­es ex­act­ly their ap­petite for bold vi­sions in the fu­ture of med­i­cine, with the po­ten­tial to de­liv­er “life-chang­ing out­comes” for pa­tients with mus­cle dis­eases, he said.

This is how the biotech plans to do it: By link­ing an an­ti­body to an oligonu­cleotide, Dyne’s ther­a­pies are en­gi­neered to hone in on mus­cle cells and de­grade on­ly dis­ease-caus­ing RNA, there­by avoid­ing sys­temic tox­i­c­i­ty is­sues.

Ro­mesh Sub­ra­man­ian

Ro­mesh Sub­ra­man­ian, a co-founder of what is now Trans­late Bio, helped launch the op­er­a­tions as an en­tre­pre­neur-in-res­i­dence at At­las. He’s since hand­ed the CEO ba­ton to Joshua Brumm and moved to the CSO post.

“When you de­liv­er a naked oli­go, very lit­tle gets to the mus­cle,” he told C&EN back in 2019.

That means a lack of speci­fici­ty and po­ten­tial safe­ty prob­lems for drugs like Sarep­ta’s con­tro­ver­sial Ex­ondys 51. While Dyne is aim­ing di­rect­ly at that mar­ket with its Duchenne mus­cu­lar dy­s­tro­phy pro­gram, its ini­tial fo­cus is on my­oton­ic dy­s­tro­phy.

Trail­ing close­ly is a third ther­a­py for fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy, fol­lowed by dis­cov­ery work in the car­diac and meta­bol­ic are­nas.

Su­san­na High

How would the ap­proach com­pare to gene ther­a­pies, which are crop­ping up at Sarep­ta and oth­er new­er play­ers fo­cused on mus­cle dis­eases? We didn’t get a chance to ask Dyne, which is shy­ing away from in­ter­views this morn­ing — per­haps a sign of up­com­ing plans in a boom­ing biotech IPO mar­ket.

Un­der Brumm, Dyne has been on a bit of a hir­ing spree re­cent­ly, poach­ing Su­san­na High from blue­bird to be COO, ap­point­ing ex-Cel­gene ex­ec Daniel Wil­son as VP of in­tel­lec­tu­al prop­er­ty, and scoop­ing De­bra Feld­man from Sage Ther­a­peu­tics as head of reg­u­la­to­ry.

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Samit Hirawat (Bristol Myers Squibb)

Af­ter bruis­ing re­jec­tion, blue­bird and Bris­tol My­ers Squibb land ide-cel pri­or­i­ty re­view. But will it mat­ter for the CVR?

With the clock all but up, the FDA accepted and handed priority review to Bristol Myers Squibb and bluebird bio’s BCMA CAR-T, keeping a narrow window open for Celgene investors to still cash in on the $9 CVR from the $63 billion Celgene merger.

The acceptance comes five months after the two companies weres slammed with a surprise refuse-to-file that threatened to foreclose the CVR entirely. Today’s acceptance sets the FDA decision date for March 27, 2021 – or precisely 4 days before the CVR deadline of March 31. Given the breakthrough designation and strong pivotal data — 81.5% response rate, 35.2% complete response rate — priority review was largely expected.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicx­i's David Grainger and Francesco De Ru­ber­tis pump €200M in­to six com­pa­nies and what they say is a first-of-its kind fund

In what they’re billing as a first for biotech, David Grainger, Francesco De Rubertis and their team at Medicxi have put down a €200 million to sweep up stakes in six companies from their predecessor VC and pump new money into them.

Medicxi didn’t disclose which companies it was investing in but the portfolio draws from Index Ventures Life VI, one of the last funds the Medicxi team launched while they were still part of the multinational, tech-focused VC firm Index Ventures. That team kept advising Index on their life sciences portfolio even after they spun out to form their own firm in the middle of 2016.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Can a mag­net­ic cell ther­a­py re­place corneal trans­plan­ta­tion? As eight-year jour­ney leads to the clin­ic, two broth­ers un­veil bold vi­sion

Jeff Goldberg was getting acquainted with a brand new way to do corneal transplants when an even newer, even bolder idea hit him.

It was almost 10 years ago, and Goldberg was in his first faculty position at Bascom Palmer Eye Institute at the University of Miami. Scientists had developed a new way to do cornea transplants where instead of sewing a whole donor cornea — a decades-old practice — they were just engrafting the inner layer of cells.

News brief­ing: Tiny Vac­cinex's drug flops in PhII Hunt­ing­ton's tri­al, stock craters; Siol­ta nabs $30M Se­ries B to de­vel­op mi­cro­bio­me drug

Siolta Therapeutics, a microbiome company targeting allergic diseases, raked in a $30 million Series B to develop its lead candidate, STMC-103H. The drug, which has been FDA fast-tracked, is headed for proof-of-concept trials, according to the company. Its various indications include allergic asthma, food allergies, atopic dermatitis, allergic rhinitis, and allergy prevention.

The news comes just after the California-based biotech added a prominent biopharma veteran as an advisor: 20-year Gilead CEO John Martin. The biotech also gained Richard Shames as CMO, who came by way of Protagonist Therapeutics.

Embattled CDC director Robert Redfield (AP Images)

Covid-19 roundup: CDC ad­vi­so­ry com­mit­tee de­lays pri­or­i­ty dis­tri­b­u­tion vote; EU re­port­ed­ly in­dem­ni­fy­ing vac­cine mak­ers

A federal committee that advises the CDC was expected to hold a vote Tuesday on a plan regarding the distribution for initial doses of approved Covid-19 vaccines. But that vote has been scrapped.

The Advisory Committee on Immunization Practices, or ACIP, won’t be voting until the committee members learn more about which vaccines become available first, the Wall Street Journal reported. The vote could potentially wait until a specific vaccine is authorized before recommending how to dole out the first doses.

Anthony Coyle (Pfizer via Youtube)

Flag­ship's merged biotech Reper­toire nets ex-Pfiz­er CSO An­tho­ny Coyle as R&D chief

Flagship is building a big-name C-Suite at its new, $220 million merged biotech.

Repertoire Immune Medicines, which already boasts former Bioverativ chief John Cox as its CEO, announced yesterday that Anthony Coyle, the former Pfizer CSO and the founding CEO of Pandion, will join as their head of R&D.

“As we progress clinical trials for our multi-clonal T cell candidates in immuno-oncology, Tony’s deep expertise in cellular immunology and novel therapeutic development will help us achieve our vision of creating a new class of transformative medicines for patients,” Cox said in a statement.

President Donald Trump (via AP Images)

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists. HHS con­tin­ues to claim Azar “will de­fer com­plete­ly to the FDA"

President Donald Trump, who seems intent on announcing a Covid-19 vaccine before Election Day, could legally authorize a vaccine over the objections of experts, officials at the FDA and even vaccine manufacturers, who have pledged not to release any vaccine unless it’s proved safe and effective.

In podcasts, public forums, social media and medical journals, a growing number of prominent health leaders say they fear that Trump — who has repeatedly signaled his desire for the swift approval of a vaccine and his displeasure with perceived delays at the FDA — will take matters into his own hands, running roughshod over the usual regulatory process.

Zai Lab hauls in $761M from Hong Kong IPO to push Ze­ju­la, more bud­ding can­di­dates in Chi­na — re­port

Zai Lab is set to net more than $761 million from its secondary listing in Hong Kong after pricing the IPO at $72.51 (HKD$562) — just a hair below its Nasdaq closing price on Monday, Bloomberg and Nikkei Asian Review reported.

A pioneer in bringing Western drugs to China, co-founder and CEO Samantha Du has more than tripled Zai Lab’s market cap in the three years it’s been public in the US. The HKEX listing is designed to fund R&D and commercialization for the current portfolio while fueling new in-licensing pacts, the biotech wrote in a filing.